ERBB3 and non-small cell lung carcinoma: This modality has been applied to degrade the pseudokinase Her3, an undruggable target implicated in breast, ovarian and non-small cell lung cancers, by bifunctional molecules consisting of a covalent Her3 targeting small molecule linked to a hydrophobic adamantane moiety [82].